Want to join the conversation?
$BIIB 2Q15 PR: TECFIDERA revenues were $883MM, up 7% vs. $700MM in 2Q14; TECFIDERA now the most prescribed oral MS therapy globally. Interferon revenues, including AVONEX and PLEGRIDY, were $690MM vs. $774MM in 2Q14. TYSABRI revenues were $463MM vs. $533MM in 2Q14. Revenues for FAMPYRA and FUMADERM were $34MM vs. $38MM in 2Q14.
$FOXA just entered into a preliminary deal with Sky plc under which it will acquire all shares, or should I say remaining shares for a total value of $23 billion. The sleeping fox catches no poultry, but this fox just caught something that’s a lot bigger than poultry.
$BIG looks promising to me. Feels like it’s a good time to put some money on it.
$TWTR rolled out an iOS update Dec. 8 night that killed its famous "@" symbol. This lead to confusion among the iOS users when they tried it to reply to tweets.